Endurazymes lands exclusive LANL enzyme technology license

EnduraFAST's Endurazymes has signed an exclusive license with Los Alamos National Laboratory for enzyme engineering technology that tests performance under relevant operating conditions. The deal gives the company a scientific base for its first commercial platform as industrial biology moves closer to real-world manufacturing use.

Why it matters: - The agreement gives Endurazymes access to technology designed to show how enzymes perform in real-world operating conditions, not just in the lab. - Better performance data can reduce risk for companies deciding whether to invest time and money in enzyme development. - The deal supports commercialization of industrial biology across manufacturing, energy, agriculture, mining, environmental technologies and pharmaceuticals.

What happened: - EnduraFAST Inc., doing business as Endurazymes, announced an exclusive license agreement with Los Alamos National Laboratory on October 1, 2026. - The license covers advanced enzyme engineering technology developed at LANL. - The technology is designed to evaluate enzyme performance under relevant operating conditions. - Endurazymes said the agreement establishes the scientific foundation for its first commercial platform.

The details: - The licensed technology generates experimental data under relevant operating conditions. - That data is intended to identify enzyme candidates that are more likely to succeed in commercial applications. - Endurazymes said the approach is meant to improve confidence in enzyme performance as biological innovations move from research toward practical use. - Andrew DeLuise, chief executive officer of Endurazymes, said the company was founded to give researchers and commercial partners better data for faster and more confident commercialization decisions. - Melissa Fox, senior director of the Partnerships and Pipelines Office at LANL, said exclusive licenses help advance the laboratory's technology transfer mission and move research into industry partnerships. - LANL said its participation in the announcement is limited to factual statements about the technology and licensing relationship and does not represent an endorsement of Endurazymes or its products. - Endurazymes is the commercial brand of EnduraFAST Inc. - The company says it develops technologies that improve confidence in how enzymes will perform under real-world operating conditions. - More information is available at the company's website.

Between the lines: - The deal points to a broader push to turn enzyme discovery into a more predictable commercial process. - That matters because enzyme performance can vary once a product leaves controlled lab conditions and enters industrial settings. - An exclusive license also gives Endurazymes a clearer path to differentiate its first platform in a crowded industrial biology market.

What's next: - Endurazymes is likely to use the licensed technology as the technical base for its first commercial platform. - The company will need to prove the platform can deliver useful data for partners evaluating enzyme candidates. - Broader market adoption will depend on whether the technology helps shorten development timelines and lower commercialization risk.